Matinas BioPharma Q2 net loss $6.1M; FDA sets 700-patient bar for MAT2203 first-line

Matinas BioPharma Holdings, Inc.

2023-Q2 EPS reported -$0.05 revenue$1,096,000

Q2 2023 revenue $0 (vs $1.1M in Q2 2022); net loss $6.1M ($0.03/sh) vs $5.9M.
Cash and securities $22.5M at June 30, down from $28.8M; runway into Q3 2024.
FDA requires ~700-patient non-inferiority trial (10% mortality margin) for first-line MAT2203 approval.
Compassionate use: 15-year-old with leukemia and resistant mucor/aspergillus improved on MAT2203, no nephrotoxicity.
Internal RNAi show in vitro activity; in vivo oral LNC data expected H2 2023.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Matinas BioPharma Holdings, Inc. reported the three and six months ended June 30, 2023 results: revenue no revenue.

Period: the three and six months ended June 30, 2023
Revenue: no revenue
Result: reported results

Exact text from the filing

Matinas BioPharma (NYSE American: MTNB), a clinical-stage biopharmaceutical company focused on delivering groundbreaking therapies using its lipid nanocrystal (LNC) platform delivery technology, reports financial results for the three and six months ended June 30, 2023 and provides a business update.

View on SEC.gov

3 earnings releases filed in the last 30 days. Browse all earnings releases →

Matinas BioPharma Holdings, Inc. filing history →

Source: SEC EDGAR

accession 0001493152-23-027349

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.